Catalent (CTLT)
(Delayed Data from NYSE)
$55.92 USD
+0.12 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth B Momentum C VGM
Catalent (CTLT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$60.07 | $63.50 | $47.00 | 7.65% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Catalent comes to $60.07. The forecasts range from a low of $47.00 to a high of $63.50. The average price target represents an increase of 7.65% from the last closing price of $55.80.
Analyst Price Targets (7 )
Broker Rating
Catalent currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, two are Strong Buy, representing 20% of all recommendations. A month ago, Strong Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 4 |
Buy | 0 | 0 | 0 | 0 | 2 |
Hold | 8 | 8 | 8 | 8 | 6 |
Sell | 0 | 0 | 0 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.60 | 2.60 | 2.60 | 2.73 | 2.27 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Stephens | Jacob Johnson | Hold | Hold |
2/9/2024 | William Blair | Maxwell A Smock | Hold | Hold |
1/8/2024 | Robert W. Baird & Co. | Eric W Coldwell | Strong Buy | Strong Buy |
9/5/2023 | Argus Research Corp. | David A Toung | Hold | Strong Buy |
8/29/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.60 |
ABR (Last week) | 2.60 |
# of Recs in ABR | 10 |
Average Target Price | $60.07 |
LT Growth Rate | 33.10% |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 0.24 |